Clinical Trial Update: Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P [Phase 1]

View source ↗

Summary

Phase 1 trial assessing itch control with VLY-686 in healthy volunteers after intradermal injections of Substance P has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pruritus

Drugs mentioned

• VLY-686

Snippet

Sponsor: Vanda Pharmaceuticals | Conditions: Pruritus | Phase 1 | Status: COMPLETED